Podium to Practice: ASH® 2025 – LEUKEMIA: GIMEMA ALL2820

Podium to Practice: ASH® 2025 – LEUKEMIA: GIMEMA ALL2820

Podium to Practice: ASH® 2025
Explore more from your favourite experts – click their name to access their entire library of content.
Icon Chair Speaker

Chair

Dr. Jorge Cortes

Icon Chair Speaker

Speakers

Dr. Lynn Savoie

Dr. Brian Leber

Studies / Trials Discussed

ID 439 – First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients

This program has been made possible through unrestricted support from Astellas and Daiichi Sankyo.

Studies/trials discussed:

ID 439 – First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients
Tagged